Does co-option of Liver Vessels and Not Sprouting Angiogenesis drive Acquired Sorafenib Resistance in Hepatocellular Carcinoma?
This is the first documentation of vessel co-option as a mechanism of acquired resistance to anti-angiogenic therapy and could have important implications including the potential therapeutic benefits of targeting vessel co-option in conjunction with vascular endothelial growth factor receptor signaling.
After accounting for differing injury severity, patients with their two worst injuries in different body regions have higher mortality than those with their two worst injuries in the same region. Results suggest that the observed effect is not due to a foible in the Abbreviated Injury Scale system but rather to physiologic, clinical, or organizational elements. The results of this study should be considered in the development of future injury severity instruments and may have implications for the care of patients with multiple injuries.